Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$2.22M-$2.22MN/M vs Q1 2025 EPS Diluted-$4.18-$4.18N/M vs Q1 2025 Operating Income-$2,283,739N/M Operating Cash Flow-$2,889,329N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 8, 2026 · 38 d after period end